Actinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Providing Update on Company Progress and Anticipated Milestones Aug 4, 2016
Actinium Pharmaceuticals Highlights Successful Investigator Meeting for Pivotal Phase 3 Iomab-B SIERRA Trial Jul 20, 2016
Actinium Receives Assignment of Intellectual Property From Memorial Sloan Kettering Cancer Center Specific to Actinium's APIT Platform and the Use of Actinium-225 Jul 12, 2016
Actinium Pharmaceuticals to Sponsor Investigator Meeting for Pivotal Phase 3 SIERRA Trial for Iomab-B Jul 6, 2016
Actinium Sponsored Acute Myeloid Leukemia (AML) Awareness Month to Feature Webinar Focused on Transplantation as a Treatment Option for Blood Cancers Jun 28, 2016
Actinium Sponsored Acute Myeloid Leukemia (AML) Awareness Month Continues With Medical Update Webinar Jun 15, 2016
Actinium Announces Strong Presence at Society of Nuclear Medicine and Molecular Imaging Annual Meeting Jun 9, 2016
Actinium to Present at BIO International Convention to Provide Updates on Actimab-A and Iomab-B Programs Jun 8, 2016
Actinium Pharmaceuticals Announces Positive Safety and Efficacy Results From Phase 1 Actimab-A Trial in Patients With Newly Diagnosed Acute Myeloid Leukemia and Provides Guidance on Plans for Phase 2 Clinical Trial Jun 1, 2016